Effective Botulinum Toxin Injection Guide for Treatment of Temporal Headache

被引:15
作者
Choi, You-Jin [1 ]
Lee, Won-Jae [1 ]
Lee, Hyung-Jin [1 ]
Lee, Kang-Woo [1 ]
Kim, Hee-Jin [1 ]
Hu, Kyung-Seok [1 ]
机构
[1] Yonsei Univ, Human Identificat Res Inst, PLUS Project BK21, Div Anat & Dev Biol,Dept Oral Biol,Coll Dent, Seoul 03722, South Korea
来源
TOXINS | 2016年 / 8卷 / 09期
基金
新加坡国家研究基金会;
关键词
migraine; botulinum toxin type A; temporalis muscle; injection site; Sihler staining; ONABOTULINUMTOXINA; MIGRAINE;
D O I
10.3390/toxins8090265
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
This study involved an extensive analysis of published research on the morphology of the temporalis muscle in order to provide an anatomical guideline on how to distinguish the temporalis muscle and temporalis tendon by observing the surface of the patient's face. Twenty-one hemifaces of cadavers were used in this study. The temporalis muscles were dissected clearly for morphological analysis between the temporalis muscle and tendon. The posterior border of the temporalis tendon was classified into three types: in Type I the posterior border of the temporalis tendon is located in front of reference line L2 (4.8%, 1/21), in Type II it is located between reference lines L2 and L3 (85.7%, 18/21), and in Type III it is located between reference lines L3 and L4 (9.5%, 2/21). The vertical distances between the horizontal line passing through the jugale (LH) and the temporalis tendon along each of reference lines L0, L1, L2, L3, and L4 were 29.7 +/- 6.8 mm, 45.0 +/- 8.8 mm, 37.7 +/- 11.1 mm, 42.5 +/- 7.5 mm, and 32.1 +/- 0.4 mm, respectively. BoNT-A should be injected into the temporalis muscle at least 45 mm vertically above the zygomatic arch. This will ensure that the muscle region is targeted and so produce the greatest clinical effect with the minimum concentration of BoNT-A.
引用
收藏
页数:10
相关论文
共 16 条
  • [1] Bendtsen Lars, 2009, Ther Adv Neurol Disord, V2, P155, DOI 10.1177/1756285609102328
  • [2] Carruthers J, 2001, Facial Plast Surg Clin North Am, V9, P197
  • [3] CGRP and VIP Levels as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine
    Cernuda-Morollon, Eva
    Martinez-Camblor, Pablo
    Ramon, Cesar
    Larrosa, Davinia
    Serrano-Pertierra, Esther
    Pascual, Julio
    [J]. HEADACHE, 2014, 54 (06): : 987 - 995
  • [4] Botox Treatment for Migraine and Chronic Daily Headache in Adolescents
    Chan, Valerie W.
    McCabe, E. Jane
    MacGregor, Daune L.
    [J]. JOURNAL OF NEUROSCIENCE NURSING, 2009, 41 (05) : 235 - 243
  • [5] Clinical Uses of Botulinum Neurotoxins: Current Indications, Limitations and Future Developments
    Chen, Sheng
    [J]. TOXINS, 2012, 4 (10) : 913 - 939
  • [6] Botulinum neurotoxin for the treatment of migraine and other primary headache disorders
    Dodick, D
    Blumenfeld, A
    Silberstein, SD
    [J]. CLINICS IN DERMATOLOGY, 2004, 22 (01) : 76 - 81
  • [7] Insights Into the Mechanism of OnabotulinumtoxinA in Chronic Migraine
    Durham, Paul L.
    Cady, Roger
    [J]. HEADACHE, 2011, 51 (10): : 1573 - 1577
  • [8] Myofascial trigger points and their relationship to headache clinical parameters in chronic tension-type headache
    Fernandez-de-las-Penas, Cesar
    Alonso-Blanco, Cristina
    Luz Cuadrado, Maria
    Gerwin, Robert D.
    Pareja, Juan A.
    [J]. HEADACHE, 2006, 46 (08): : 1264 - 1272
  • [9] Göbel H, 2001, J NEUROL, V248, pS34
  • [10] Botulinum toxin a for axillary hyperhidrosis (excessive sweating).
    Heckmann, M
    Ceballos-Baumann, AO
    Plewig, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (07) : 488 - 493